Clinical Trial Update: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with doxorubicin or anti-estrogen therapy in metastatic breast cancer (both triple-negative and hormone receptor–positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anti-estrogen therapy
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Status: COMPLETED | Results posted: 2023-04-19